A comparison of the efficacy and safety of complementary and alternative therapies for ulcerative colitis

Lu, Meiqi; Zhang, Ting; Lu, Zhen; Wang, Wei; Chen, Ting; Cao, Zhiqun

doi:10.1097/md.0000000000021219

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 Known for its ability to reduce inflammation and alleviate symptoms in individuals with inflammatory conditions, adalimumab targets TNF-α and mitigates its inflammatory effects, leading to reduced inflammation and symptom relief. 21 The result of most studies indicates that adalimumab has been effective in improving the initial stage of moderate to severe active UC patients. 22,23 Our study aims to determine the effectiveness of adalimumab in treating severe UC.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis

Azadbakht,

Seighali,

Azadbakht

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

Background and AimUlcerative colitis (UC) causes chronic inflammation in the digestive tract, leading to abdominal pain and diarrhea. Adalimumab, a monoclonal antibody, is used to treat moderate to severe cases. This review and meta‐analysis evaluated adalimumab's effectiveness for severe UC, considering patient age, disease duration, and gender.MethodsThis study was designed as a systematic review and a meta‐analysis. Articles were searched in PubMed, Scopus, and Web of Science databases based on the keywords of adalimumab and UC. The titles, the abstracts, and, if necessary, the full texts of the articles were read. Then for further review, the full texts of the related articles were carefully examined, and the final articles were selected. Seventy‐eight articles were searched based on the keywords, and after reading the articles, 50 articles were related to the topic of the dissertation. The 50 articles were evaluated critically based on a checklist prepared by a statistical consultant and four articles with a score above 70% were selected. In the four articles, the main indicators of the effectiveness of adalimumab, including mucosal healing, clinical remission, and clinical response, were evaluated.ResultsThe effectiveness of adalimumab on the mucosal healing index was 75.40%, the clinical remission index was 70.79%, and the clinical response index was 83.02%, based on different doses and treatment durations in the study. In the four meta‐analysis studies on adalimumab's effectiveness, 1613 UC patients were treated with varying doses over 8 and 52 weeks. Based on a meta‐analysis over 8 and 52 weeks for treating moderate to severe UC, adalimumab's effectiveness was 70%−83%. The highest effectiveness, based on three main indices, was with a 40 mg dose over 52 weeks.ConclusionAccording to the meta‐analysis, the effectiveness of adalimumab for treating moderate to severe UC over 8 and 52 weeks was 70%−83%. The highest effectiveness, based on three main indices, was with a 40 mg dose over 52 weeks.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis

Azadbakht,

Seighali,

Azadbakht

et al. 2024

Health Science Reports

View full text Add to dashboard Cite

show abstract

Network pharmacology and molecular docking study of Ermiaosan (二妙散) in the treatment of ulcerative colitis with dampness-heat syndrome

Qu,

Li,

et al. 2024

Discov Appl Sci

View full text Add to dashboard Cite

Objective To study Ermiaosan in the treatment of UC by using network pharmacology and molecular docking, and to provide references for experiments and clinical application for treating UC with dampness-heat syndrome. Methods The main active chemical components of Ermiaosan were screened out through TCMSP, the targets of components were obtained from TCMSP, the SwissTargetPrediction, TTD and the DrugBank database, and these targets genes were retrieved by UniProt database, the disease genes were obtained from TTD and Genecard database. String tool was used to constructed the PPI network, to built these components and their corresponding targets, Cytoscape software was applied to merge the networks and screen out the core network. And Bioinformatic analysis was performed using the OECloud tools to explore the enrichment analyses of GO and KEGG. Molecular docking was applied to check the affinity between the components and selected targets. Results Forty-six main active components were predicted from Ermiaosan, and 408 intersection genes were screened from drug-disease genes. The enrichment included PI3K–Akt, TNF and HIF-1 signaling pathway, and the networks analysis showed that Ermiaosan acted on seven key targets AKT1, TNF, IL6,TP53, VEGFA, IL1B and CTNNB1 to play roles in treating UC. Molecular docking showed that top 3 chemical components could bind stably with these targets. Conclusion Ermiaosan can relieve dampness-heat syndrome of UC, the possible potential mechanism might be related to the targets AKT1, TNF, IL6,TP53, VEGFA, IL1B and CTNNB1 linked with TNF, PI3K-Akt, and HIF-1 signaling pathway, it will provide meaningful references for further study in experiments and clinical investigations.

show abstract

Efficacy and safety of acupoint catgut-embedding for ulcerative colitis

et al. 2020

View full text Add to dashboard Cite

Background: Ulcerative colitis (UC) is a refractory intestinal disease prone to recurrent attacks, with a high rate of canceration, which seriously affects life treatment. Routine treatment has disadvantages such as long course of treatment, high cost, easy recurrence and limited effectiveness. Clinical practice shows that acupoint catgut embedding therapy has certain therapeutic advantages but lacks evidence of evidence-based medicine. The purpose of this study is to systematically study the effectiveness and safety of acupoint catgut embedding for ulcerative colitis. Methods: Retrieve English database (PubMed, Embase, Web of Science, the Cochrane Library) and Chinese database (CNKI, CDDB, CQVIP, CBM) by computer, and manually retrieve Baidu and Google Academy for randomized controlled trials (RCTs) of acupoint catgut embedding therapy for ulcerative colitis from the time of construction of database to September 2020. Two researchers independently extracted data and evaluated the quality of the literature included in the study, and used RevMan 5.3 software for meta-analysis of the included literature. Result: The study evaluated the effectiveness and safety of acupoint catgut embedding for ulcerative colitis through efficiency, symptom score, colonoscopy score, mucosal healing rate, recurrence rate, incidence of adverse reactions, etc. Conclusion: This study will provide reliable evidence-based evidence for clinical application of acupoint catgut embedding therapy for ulcerative colitis. OSF Registration number: DOI 10.17605/ OSF.IO / 7T4QV.

show abstract

A comparison of the efficacy and safety of complementary and alternative therapies for ulcerative colitis

Cited by 3 publications

References 29 publications

Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis

Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis

Network pharmacology and molecular docking study of Ermiaosan (二妙散) in the treatment of ulcerative colitis with dampness-heat syndrome

Efficacy and safety of acupoint catgut-embedding for ulcerative colitis

Contact Info

Product

Resources

About